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of the tyrosine kinase domain of epider-
mal growth factor receptor (EGFR), 
gefitinib and erlotinib, in patients 
with EGFR mutations result in 70% 
to 80% responses.1,2 Ninety percent of 
these consist of deletions of exon 19 
and p.L858R mutations on exon 21.2 
However, through diverse mechanisms3 
resistance will eventually appear. There 
are also a minority of infrequent EGFR 
mutations at diagnosis whose predictive 
role is poorly characterized.4
We present two cases of patients 
diagnosed with a lung adenocarci-
noma harboring rare EGFR mutations 
that received treatment with gefitinib. 
Mutational analysis was performed by 
polymerase chain reaction amplification 
of exons 18, 19, 20 and 21 of the EGFR 
gene and exon 1 of the KRAS gene fol-
lowed by direct sequencing using BigDye 
3.1 (Applied Biosystems, Foster City, 
CA) and analysis in a Genetic Analyzer 
3500Dx (Applied Biosystems).
CASE 1
A white, 81-year-old, male 
exsmoker was diagnosed in July 2010 of 
a stage IIIA (T4N0M0) lung adenocarci-
noma. Molecular analysis demonstrated 
the presence of a p.R836C mutation in 
exon 21 of the EGFR gene. He began 
first-line chemotherapy with a platinum 
doublet. Response assessment by com-
puted tomography scan showed stabiliza-
tion. However, because of symptomatic 
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progression he started treatment with 
gefitinib 250 mg/day. In January 2011 
he was admitted in hospital because of 
increasing dyspnoea and pain. The com-
puted tomography scan showed progres-
sion of the tumor with appearance of 
pleural effusion. The study of the fluid 
confirmed the diagnosis of metastasis 
from adenocarcinoma harboring the 
p.R836C mutation on exon 21 (Fig. 1A). 
No p.T790M mutation on exon 20 or 
hepatocyte growth factor receptor (MET) 
amplification was detected. Progressive 
disease led to rapid deterioration of per-
formance status and the patient died in 
early March 2011.
CASE 2
A white, 54-year-old, heavy 
smoker man was diagnosed in May 
2011 with a lung adenocarcinoma stage 
IIIB (T4N2M0) not suitable for radical 
treatment. Evaluation of EGFR muta-
tional status demonstrated the presence 
of the p.T854S mutation in exon 21. 
No wild-type allele was detected in this 
position, indicating that the mutation 
was either hemizygous or homozygous 
(Fig. 1B). He started treatment with 
gefitinib and early (6 weeks) assessment 
by computerized tomography demon-
strated progressive disease. He received 
subsequent lines of treatment with sta-
ble disease as best response. Local and 
central nervous system progression led 
FIGURE 1.  Sequencing chromatograms showing EGFR mutations affecting cases 1 
and 2. A, Case 1-arginine(R) to cysteine (C) substitution at amino acid position 836 
(p.R836C) resulting from a CGC→TGC exchange. B, Case 2-threonine (T) to serine 
(S) substitution at amino acid position 854 (p.T854S) resulting from a ACA→TCA 
exchange.
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to important clinical deterioration and 
death in March 2012.
DISCUSSION
The finding of EGFR mutations 
not previously described always confers 
the challenge of treatment decision. 
For this reason we report these cases of 
patients with infrequent EGFR muta-
tions on exon 21 with rapid progres-
sion on gefitinib treatment. Upcoming 
results of newly available EGFR inhibi-
tors such as afatinib or dacomitinib will 
show whether these drugs will be effec-
tive for this subset of patients.
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